Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2016 DISEASE NETWORK REGISTRY PROJECTS LOGIN
 
 
  
Experimental Rx -
--->Uutiset
[-]Projekti
--->Rahoittaja
--->[-]Johtokunta
--->Arnesen
--->Blumenstein
--->Burgunder
--->Craufurd
--->Humbert
--->Jones
--->Kremer
--->Reilmann
--->Roos
--->Rosser
--->Weydt
--->Capper-Loup
--->Feihle
--->Levey
--->McLean
--->Julkiset asiakirjat
--->[+]Writing Committee Strategic ...
--->[-]Neuvoa antava lautakunta
--->Becanovic
--->Busse
--->Frontali
--->Giorgini
--->Holmans
--->Mariotti
--->Norremolle
--->Reetz
--->Rickards
--->Saft
--->van Duijn
--->Valenza
--->Verellen
--->Julkiset asiakirjat
--->Keskuskoordinaatio
--->Kielikoordinaatio
--->Fellowship Programme
--->[-]Perustuslaki 2008
--->Article 1
--->Article 2
--->Article 3
--->Article 4
--->Article 5
--->Article 6
--->Article 7
--->Article 8
--->Article 9
--->Article 10
--->Article 11
--->Article 12
--->Documents
--->[-]Äänestys
--->[-]Jäsenet
--->Jäsenyyden hakeminen
[-]Tutkimuspaikat
--->[+]Itävalta
--->[+]Belgia
--->[+]Tsekin tasavalta
--->[+]Tanska
--->[+]Suomi
--->[+]Ranska
--->[+]Saksa
--->[+]Ireland
--->[+]Italia
--->[+]Alankomaat
--->[+]Norja
--->[+]Puola
--->[+]Portugali
--->[+]Russia
--->[+]Espanja
--->[+]Ruotsi
--->[+]Sveitsi
--->[+]Iso-Britannia
--->[+]Outside Europe
[-]Työryhmät
--->[-]Advanced HD
--->Dates
--->[+]Meetings
--->[+]Behavioural Phenotype
--->[-]Biological Modifiers
--->Dates
--->[+]Meetings
--->[-]Biomarkers
--->[+]Päivämäärät
--->[+]Meetings
--->[+]Brainbanking
--->[+]Cognitive Phenotype
--->[-]Environmental Modifiers
--->[+]Dates
--->[+]Meetings
--->[-]Functional Ability
--->Dates
--->[+]Meetings
--->[+]Genetic Testing
--->[+]Genetic Modifiers
--->[+]Health Economics
--->[-]Imaging
--->[+]Päivämäärät
--->[+]Meetings
--->[+]Juveniili Huntingtonin tauti
--->[+]Motor Phenotype
--->[+]Neuroprotective Rx
--->[-]Physiotherapy
--->Dates
--->[+]Meetings
--->[-]Quality of Life
--->[+]Päivämäärät
--->[+]Meetings
--->[-]Standard of Care
--->[+]Päivämäärät
--->[+]Meetings
--->[+]Dieticians
--->[+]SALT
--->[+]Dental care
--->[+]Occupational
--->[+]Surgical Therapy
--->[-]Symptomatic Rx
--->[+]Päivämäärät
--->[+]Meetings
--->[+]Young Adults
[-]Tapahtumat
--->[+]EHDN 2016
--->EHDN 2014
--->[-]EHDN 2012
--->Introduction
--->Announcement
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Important Dates
--->Registration
--->[+]Travel & Accommodation
--->[+]EHA Registration
--->EHA Programme
--->Reception Dinner
--->About Stockholm
--->[+]Abstract Submission
--->Reimbursement
--->[-]Documents
--->Handouts
--->Presentations
--->[-]Posters
--->Pathogenic mechanisms
--->Animal models
--->Choreatic disorders - no...
--->Genetic modifiers
--->Wet Biomarkers
--->Imaging
--->Clin characteristics
--->Clin char-motor
--->Clin char-cognitive
--->Clin char - behaviour
--->Clin char-other
--->Clinical studies
--->Genetic testing
--->Clinical care
--->Experimental Rx
--->Clinical Rx
--->Non-scientific
--->Contacts
--->Feedback & Evaluation
--->[+]EHDN 2010
--->[+]EHDN 2008
--->[+]EHDN 2007
--->[+]EHDN 2006
--->[+]EHDN 2005
--->[+]EHDN 2004
[-]Yhteydenpito
--->Yhteydenottolomake
--->Chatti-huoneet
--->Sähköpostilistat - julkinen
--->Newsletter
--->Työtarjoukset
päivämääräkuvauskokokirjoittaja asiakirja 
04.08.26In vivo efficacy of (CUG)n oligonucleotides to treat HD32 kBanonymousapplication/mswordp02-in-vivo-efficacy-oligonucleotides 
04.08.26Antisense oligonucleotide mediated transcript reduction and modulation – the European approach to develop a therapy for Huntington Disease32 kBanonymousapplication/mswordp01-antisense-oligonucleotide-transcript 
04.08.26Reducing toxic n-terminal Huntingtin fragments in HD using exon skipping32 kBanonymousapplication/mswordp03-exon-skipping 
04.08.26A Huntingtin peptide inhibits polyQ-hHtt associated defects32 kBanonymousapplication/mswordp04-polyq-hhtt-associated-defects 
04.08.26Astrocytes affect neuroprotection: Glatiramer acetate in Huntington`s Disease therapy32 kBanonymousapplication/mswordp07-glatiramer-acetate 
04.08.26Olesoxime improves specific features of the HD pathology32 kBanonymousapplication/mswordp06-olesoxime 
04.08.26Analysis of Nrf2-downstream targets after fumarate treatment in dorsal root ganglia – an anti-inflammatory therapy in neurodegenerative disease?!32 kBanonymousapplication/mswordp08-analysis-of-nrf2 

Kansio sisältää 7 asiakirjaa.
about us | privacy statement | disclaimer | terms of use